We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

An advantage on paper

19 November 2007 By Robert Cyran

Celgene could have found $3bn to buy smaller rival Pharmion from cash on hand. But it had a more valuable currency its richly valued stock. Biotech groups high multiples and their growing ambitions could derail big pharma s acquisition plans.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)